We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
Read MoreHide Full Article
Immunic, Inc. (IMUX - Free Report) announced that the phase II CALDOSE-1 study, which evaluated its lead candidate, vidofludimus calcium (IMU-838), for treating patients with moderate-to-severe ulcerative colitis (“UC”), did not meet the primary endpoint.
The study failed to meet the clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium as compared to placebo at week 10 — the study’s primary endpoint.
Per the company, no meaningful difference was seen between the three active dose groups for the overall intent-to-treat patient population or for the other secondary endpoints of the study — including symptomatic remission or endoscopic healing.
Following this result, the company decided to discontinue the development activities of vidofludimus calcium in UC without a partner.
Shares of Immunic were down 46.8% on Thursday following the announcement of the news. The stock has plunged 67.2% so far this year compared with the industry’s decrease of 24.4%.
Image Source: Zacks Investment Research
Immunic is developing vidofludimus calcium, a selective oral DHODH inhibitor, for treating other inflammatory and autoimmune diseases as well.
The phase III ENSURE program is evaluating vidofludimus calcium in patients with relapsing multiple sclerosis. The phase II CALLIPER study is investigating vidofludimus calcium in patients with progressive multiple sclerosis. Enrollment in both studies is ongoing.
This apart, Immunic is developing a potent and selective oral IL-17 inhibitor, IMU-935, for the treatment of psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome.
IMU-856 is being developed in diseases involving bowel barrier dysfunction. A phase I study is to evaluate IMU-856 is currently ongoing in patients with celiac disease.
Immunic has no approved product in its portfolio at the moment. Therefore, the successful development of vidofludimus calcium, along with other pipeline candidates, remains a key focus for the company.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Anavex Life Sciences’ loss per share estimates narrowed 6.6% for 2022 and 4.3% for 2023 in the past 60 days.
Earnings of Anavex Life Sciences have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AVXL delivered an earnings surprise of 0.48%, on average.
Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
Immunic, Inc. (IMUX - Free Report) announced that the phase II CALDOSE-1 study, which evaluated its lead candidate, vidofludimus calcium (IMU-838), for treating patients with moderate-to-severe ulcerative colitis (“UC”), did not meet the primary endpoint.
The study failed to meet the clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium as compared to placebo at week 10 — the study’s primary endpoint.
Per the company, no meaningful difference was seen between the three active dose groups for the overall intent-to-treat patient population or for the other secondary endpoints of the study — including symptomatic remission or endoscopic healing.
Following this result, the company decided to discontinue the development activities of vidofludimus calcium in UC without a partner.
Shares of Immunic were down 46.8% on Thursday following the announcement of the news. The stock has plunged 67.2% so far this year compared with the industry’s decrease of 24.4%.
Image Source: Zacks Investment Research
Immunic is developing vidofludimus calcium, a selective oral DHODH inhibitor, for treating other inflammatory and autoimmune diseases as well.
The phase III ENSURE program is evaluating vidofludimus calcium in patients with relapsing multiple sclerosis. The phase II CALLIPER study is investigating vidofludimus calcium in patients with progressive multiple sclerosis. Enrollment in both studies is ongoing.
This apart, Immunic is developing a potent and selective oral IL-17 inhibitor, IMU-935, for the treatment of psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome.
IMU-856 is being developed in diseases involving bowel barrier dysfunction. A phase I study is to evaluate IMU-856 is currently ongoing in patients with celiac disease.
Immunic has no approved product in its portfolio at the moment. Therefore, the successful development of vidofludimus calcium, along with other pipeline candidates, remains a key focus for the company.
Zacks Rank & Stocks to Consider
Immunic currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) , Anavex Life Sciences Corp. (AVXL - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Anavex Life Sciences’ loss per share estimates narrowed 6.6% for 2022 and 4.3% for 2023 in the past 60 days.
Earnings of Anavex Life Sciences have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AVXL delivered an earnings surprise of 0.48%, on average.
Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.